SUZHOU, China, Oct. 27, 2023 /PRNewswire/ — Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese medical device player in transcatheter structural heart device and neurovascular device, presented its GeminiOne® TEER technology, along with the early clinical experiences of the…
Coronary/Structural Heart
egnite, Inc. Unveils Research on Mitral Regurgitation at Transcatheter Cardiovascular Therapeutics Conference 2023
ALISO VIEJO, Calif.–(BUSINESS WIRE)– #digitalhealth–Key Findings: Patients with Moderate-to-Severe MR are 3x Less Likely to be Treated Than Patients with Severe MR Despite Similar Mortality
Boston Scientific AGENT™ Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial
Data from first coronary DCB study in U.S. meet 12-month primary endpoint, demonstrate low adverse event rates with AGENT DCB MARLBOROUGH, Mass. and SAN FRANCISCO, Oct. 25, 2023 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the…
Magenta Medical Reports Positive Results for US Early Feasibility Study of Elevate™ Heart Pump in Providing Temporary Mechanical Circulatory Support During High-Risk PCI Procedures Results presented at TCT 2023 in San Francisco
KADIMA, Israel and SAN FRANCISCO, Oct. 25, 2023 /PRNewswire/ — The US Early Feasibility Study of Magenta Medical’s Elevate™ System, designed to provide temporary mechanical circulatory support during high-risk percutaneous coronary intervention (HR-PCI) procedures, has successfully met…
Positive results from first-in-human completely leadless CRT in the US, published in The Journal of the American College of Cardiology
SUNNYVALE, Calif., Oct. 25, 2023 /PRNewswire/ — EBR Systems, Inc. (ASX:EBR), the medical device company developing wireless cardiac pacing systems, is proud to announce that positive results from the first completely leadless cardiac resynchronization therapy (CRT) in the United States…
TCT 2023: Six-Month Clinical Data from DESyne® BDS Plus Randomized Controlled Trial (RCT) Support Safety and Effectiveness of World’s First Site-Specific Antithrombotic Drug Therapy
SAN FRANCISCO–(BUSINESS WIRE)–Elixir Medical, a developer of novel cardiovascular technologies, today announced positive six-month clinical data from the DESyne BDS Plus Randomized Controlled Trial (RCT) evaluating DESyne BDS Plus, the world’s first triple drug-eluting coronary implant with site-specific delivery of antithrombotic drugs versus a second-generation, durable polymer drug-eluting stent (DES). The study met its primary endpoint of target lesion failure (TLF) with no TLF events rep
Heartpoint Global Wins Top Honor in TCT 2023 Shark Tank Innovation Competition
Award Recognizes Breakthrough Innovation for INTELLISTENT®, Paving the Way for Citizens Worldwide to Receive Affordable, Cutting-Edge Cardiac Care NEW YORK , Oct. 25, 2023 /PRNewswire/ — HeartPoint Global is pleased to announce that INTELLISTENT® the company’s novel multi-lumen stent…
Ventric Health Receives FDA 510(k) Clearance for Vivio®
Non-invasive medical device developed to quickly deliver the cardiovascular insights value-based care organizations need to reduce costs and improve patient lives PASADENA, Calif., Oct. 25, 2023 /PRNewswire/ — Ventric Health, a healthcare technology company and medical device provider…
Philippe Généreux, MD Presents Novel Research on Aortic Stenosis from egnite, Inc.’s Database at Transcatheter Cardiovascular Therapeutics Conference 2023
ALISO VIEJO, Calif.–(BUSINESS WIRE)– #digitalhealth–Key Findings: Patients With Aortic Stenosis (AS) Have Substantial Untreated Mortality Risk Across All Levels of AS, but AVR Remains Low
Late-Breaking Data Showcase the Benefits of Abbott’s Minimally Invasive Devices for People With Leaky Heart Valves
New data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2023 from the TRILUMINATE™ pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid regurgitation (a leaky valve) with TriClip™, an investigational device in the U.S….



